Acrux files suit over alleged patent infringements

Acrux files suit over alleged patent infringements
27 MAY 2013 10:36 AM

Drug delivery company Acrux Limited (ACR) has filed a lawsuit over claims of patent infringements against Perrigo Israel Pharmaceuticals Limited.
Acrux is involved in developing products which allow medicine to be delivered into the body through the skin.
The lawsuit is being brought by Acrux's subsidiary Acrux DDS and Eli Lilly Export over accusations that Perrigo Israel violated three of the seven US patents covering one of its products, Axiron®.
"The patents are owned by Acrux DDS Pty LTD, a wholly owned subsidiary of Acrux Limited and are exclusively licensed to Lilly," the company stated.
The claim is related to Perrigo filing with the Foods and Drugs Administration, an abbreviated new drug application (ANDA) for a testosterone metred dose transdermal solution. Acrux claims that the patent for that solution involves infringements related to its own products.
This lawsuit will be under the purview of the District Court for the Southern District of Indiana, while Acrux and Lilly have committed to maintaining the intellectual property of the product, Axiron®.
Acrux is not expecting the lawsuit to have an impact on its bottom line.
It comes after Eli Lilly, the pharmaceuticals company, announced that Axiron® produced net sales of $37.1m for the quarter to March 31.
Acrux will see a management change in August, with the company's CFO Jon Pilcher to vacate his position from August. Tony Di Petro, who has worked closely with Pilcher for the last nine years, will assume the role after Pilcher retires.
Tags: ACR Pharma, BioTech and Life Sciences Pharmaceuticals Life Sciences, Tools and Services

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.